Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

Delayed Quote. Delayed  - 08/24 10:02:03 pm
127.8 USD   -1.52%
08/23 ZIMMER BIOMET : Aug 23, 2016 Zimmer Biomet Announces Quarterly Divid..
08/17 ZIMMER BIOMET : Pharma Rock
08/15 ZIMMER BIOMET : Aug 15, 2016 Zimmer Biomet Strengthens Musculoskelet..
News SummaryMost relevantAll newsSector news 

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2012 | 12:40am CEST

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

   By Kristin Jones 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at kristin.jones@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
08/23 ZIMMER BIOMET : Aug 23, 2016 Zimmer Biomet Announces Quarterly Dividend for Thir..
08/17 ZIMMER BIOMET : Pharma Rock
08/15 ZIMMER BIOMET : Aug 15, 2016 Zimmer Biomet Strengthens Musculoskeletal Diagnosti..
08/15 ZIMMER BIOMET HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (..
08/15 ZIMMER BIOMET : Indiana company acquires CD Diagnostics
08/12 ZIMMER BIOMET HOLDINGS, INC. : Entry into a Material Definitive Agreement, Regul..
08/10 ZIMMER BIOMET : Aug 10, 2016 Zimmer Biomet Holdings Announces Pricing of Seconda..
08/09 ZIMMER BIOMET : Aims for Value with Signature Solutions
08/09 ZIMMER BIOMET : Aug 9, 2016 Zimmer Biomet Holdings Announces Launch of Secondary..
08/08 ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
08/10 FTSE notches up fifth day of gains on firm financials
08/04 Business groups sue over new U.S. limit on tax-driven foreign buyouts
08/04DJBECTON DICKINSON : Tops Earnings Views, Cuts Revenue Guidance
08/04DJBECTON DICKINSON : Tops Earnings Views, Cuts Revenue Guidance
07/28 Weak China sales drag down Smith & Nephew profits
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
08/23 Zimmer Biomet declares $0.24 dividend
08/15 Zimmer Biomet buys musculoskeletal diagnostics testing firm
08/10 Zimmer Biomet prices equity offering; shares off 3% premarket
08/04 Good Execution At Wright Medical, And Risks May Be Fenced In Now
07/29 Weight Watchers Business Model Is Not Good - Cramer's Lightning Round (7/28/1..
Financials ($)
Sales 2016 7 702 M
EBIT 2016 2 488 M
Net income 2016 454 M
Debt 2016 9 850 M
Yield 2016 0,72%
P/E ratio 2016 58,47
P/E ratio 2017 20,08
EV / Sales 2016 4,60x
EV / Sales 2017 4,25x
Capitalization 25 562 M
More Financials
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOL...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 141 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
David C. Dvorak President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Robin T. Barney Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Senior Vice President
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC12.65%120 749
TERUMO CORP14.69%16 083
C R BARD INC13.49%15 793
More Results